Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles.
A robust and targeted siRNA delivery system that effectively overcomes the historical limitations of KRAS targeting is established, providing a promising therapeutic strategy for a broad spectrum of KRAS-driven cancers.